Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>
NASDAQ | GEMP (Common Stock)
04/20/18 3:59 p.m. ET
Data provided by Nasdaq. Minimum 15 minutes delayed.
Press Releases More
Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(C)(4)04/12/18
Gemphire Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results03/15/18
Gemphire Therapeutics to Announce Fourth Quarter and Year End 2017 Financial Results on Thursday, March 1503/13/18
Investor Events More
There are currently no events scheduled.